Investigational drug · Phase 2
BMS-986548
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Malignancies.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BMS-986548"
First trial start
2026
Nov 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986548", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Malignancies
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986548" as an intervention, largest first.
- A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesNot yet recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07939815 · 171 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 29, 2029
Drug: BMS-986548; Cetuximab · For: Advanced Solid Malignancies
Sites: San Antonio, Texas; West Valley City, Utah; Vancouver, Canada · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Solid Malignancies
- PalacaparibAZD9574Phase 25 trials
AstraZeneca · Metastatic Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- BMS-986523Phase 21 trial
Bristol Myers Squibb · Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
- GIM122Phase 21 trial
Georgiamune Inc · Advanced Solid Malignancies
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.